Exhibit 10.11 SUPPLY AND DISTRIBUTION AGREEMENT: INVESTIGATIONAL PHASE THIS AGREEMENT (the "AGREEMENT") is entered into by and between OMRIX BIOPHARMACEUTICALS, LTD., an Israeli company (hereinafter, "OMRIX"), and FFF ENTERPRISES, INC., a United...Supply and Distribution Agreement • December 4th, 2006 • Omrix Biopharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
eWellness Corporation Distance Monitored Physical Therapy Programs EWELLNESS CORPORATION AND MILLENIUM HEALTHCARE, INC. SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • December 12th, 2014 • Millennium Healthcare Inc. • Wholesale-medical, dental & hospital equipment & supplies • New York
Supply and Distribution Agreement. EWC hereby enters into a Supply and Distribution agreement with MHI for EWC’s Product(s) for use as described in Exhibit A in the assigned EWC Products Territory. Subject to the terms and conditions set forth herein, EWC grants to MHI, and MHI Hereby accepts, a limited, transferable right to use its best efforts as one of EWC’s partners to promote and use the EWC’s DMpt programs.
EX-10.16 17 a2217789zex-10_16.htm EX-10.16 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities...Supply and Distribution Agreement • May 5th, 2020 • New Jersey
This SUPPLY AND DISTRIBUTION AGREEMENT (“Agreement”), dated as of January 28, 2013, is made by and between Eagle Pharmaceuticals, Inc., a Delaware corporation with its principal offices located at 470 Chestnut Ridge Road, Woodcliff Lake, New Jersey 07677 (“Eagle”), and Sandoz AG, a Swiss corporation with a corporate address at Lichtstraße 35, CH 4056 Basel, Switzerland (“Sandoz”).
EX-10.20 3 dex1020.htm SUPPLY AND DISTRIBUTION AGREEMENT SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • May 5th, 2020
EX-10.61 2 dex1061.htm SUPPLY AND DISTRIBUTION AGREEMENT Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • May 5th, 2020 • New York
This Supply and Distribution Agreement (this “Agreement”), dated as of the 13th day of October, 2006 (the “Effective Date”), is made by and between Salix Pharmaceuticals, Inc., a California corporation (“Salix”), and Watson Pharma, Inc., a Delaware corporation (“Watson”).
I. DEFINITIONS -----------Supply and Distribution Agreement • March 31st, 1998 • Nexmed Inc • Pharmaceutical preparations • New York
1 SUPPLY AND DISTRIBUTION AGREEMENT THIS AGREEMENT is made as of the 31st day of July, 1996. B E T W E E N : SUPERCRETE N/A LIMITED, a corporation incorporated pursuant to the laws of the Turks & Caicos Islands, British West Indies (hereinafter...Supply and Distribution Agreement • December 31st, 1996 • Globesat Holding Corp • Services-commercial physical & biological research
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Supply and Distribution Agreement • June 21st, 2022 • Gelesis Holdings, Inc. • Pharmaceutical preparations • Delaware
This THIRD AMENDED AND RESTATED SUPPLY AND DISTRIBUTION AGREEMENT (this “Agreement”), is made and entered into as of the 14th day of June, 2022 (the “Third Restatement Date”), by and between Roman Health Pharmacy LLC, a Delaware limited liability company, having an office at 30-30 47th Avenue, Suite 535, Long Island City, New York 11101 (“RO”) and Gelesis Inc., a Delaware corporation, having its principal office at 501 Boylston Street, Suite 6102, Boston, MA 02116 (“GELESIS”). RO and GELESIS each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
Subject to review by O2Diesel local counsel SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • January 10th, 2006 • O2diesel Corp • Wholesale-groceries & related products • Delaware
This Supply and Distribution Agreement (the “Agreement”), effective as of April 20, 2004 (the “Effective Date”), is made between [an O2Diesel corporation (“O2Diesel”), with offices at 200 Executive Drive, Newark, DE and ALOBAYA Corporation (“Distributor”) with offices at P.O.Box 1648 Al-Khobar, Kingdom of Saudi Arabia (each a “Party,” and collectively the “Parties”).
SUPPLY AND DISTRIBUTIONSupply and Distribution Agreement • February 7th, 2006 • Nutracea • Grain mill products • California
This Supply and Distribution Agreement (“Agreement”) is made to be effective as of November 4, 2005, (“Effective Date”) by and between NutraCea, a California corporation with principal address at 1261 Hawk’s Flight Court, El Dorado Hills, CA 95762 (“NutraCea”) and T. Geddes Grant, a Jamaican corporation with principal address at 109 Marcus Garvey Drive, Jamaica, W.I. The parties agree as of the Effective Date as follows:
EX-10.35 2 dex1035.htm SUPPLY AND DISTRIBUTION AGREEMENT [****] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION...Supply and Distribution Agreement • May 5th, 2020
This agreement is made as of January 1, 2005 (the “Effective Date”) by and between Biomateriali Srl, an Italian limited liability company having its registered offices at Cittadella della Ricerca s.s.7 per Mesagne, 72100 Brindisi, Italy (“BIOMATERIALI”) and Edwards Lifesciences AG, a corporation organised under the laws of Switzerland and having its business office at Chemin du Glapin 6, 1162 Saint-Prex, Switzerland (“EDWARDS”).
SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • February 27th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations
This Supply and Distribution Agreement is entered on this 20th day of May, 2011 (the “Effective Date”) between Mylan Pharmaceuticals Inc., a West Virginia corporation having its corporate offices at 781 Chestnut Ridge, Morgantown, West Virginia 26505, USA (“Mylan”); and Insys Therapeutics, Inc., a Delaware corporation having its corporate offices at 10220 South 51st Street, Suite 2, Phoenix, AZ 85044 (“Insys”).
EX-10.13 2 dex1013.htm SUPPLY AND DISTRIBUTION AGREEMENT ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406. SUPPLY AND DISTRIBUTION...Supply and Distribution Agreement • May 5th, 2020
This Supply and Distribution Agreement is entered on this 20th day of May, 2011 (the “Effective Date”) between Mylan Pharmaceuticals Inc., a West Virginia corporation having its corporate offices at 781 Chestnut Ridge, Morgantown, West Virginia 26505, USA (“Mylan”); and Insys Therapeutics, Inc., a Delaware corporation having its corporate offices at 10220 South 51st Street, Suite 2, Phoenix, AZ 85044 (“Insys”).
SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • October 31st, 2017 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
EX-10.1 2 a06-15248_1ex10d1.htm EX-10 Execution Date: May 31, 2006 AMENDED AND RESTATED SUPPLY AND DISTRIBUTION AGREEMENT between SUPERGEN, INC. (SUPPLIER) and WYETH (DISTRIBUTOR) Made Effective: 1 June 2006 CONFIDENTIAL INDEX CLAUSE 1 DEFINITIONS 3...Supply and Distribution Agreement • May 5th, 2020 • New York
WHEREAS, Distributor and Supplier are the successors in interest to that certain distribution agreement between American Cyanamid Company and Warner-Lambert Company, respectively, dated June 1, 1992 as amended on February 6, 1996 (the “Distribution Agreement”; attached hereto as Exhibit A), pursuant to which Distributor agreed, through one or more of its Affiliates, to distribute the Pentostatin-containing products under the trademark NIPENT;
Wherify Wireless, Inc. International Supply and Distribution Agreement This International Supply and Distribution Agreement ("Agreement") is entered into this 12th day of August, 2005 ("Effective Date") by and between American Network Computadores, a...Supply and Distribution Agreement • June 26th, 2006 • Wherify Wireless Inc • Services-prepackaged software • California
1 EXHIBIT 10(h) SUPPLY AND DISTRIBUTION AGREEMENT WITH BOWLINE FAMILY PRODUCTS, INC. [INNO LOGO] SUPPLY AND DISTRIBUTION AGREEMENT THIS SUPPLY AND DISTRIBUTION AGREEMENT ("Agreement") is entered into by and between Bowline Family Products, Inc.,...Supply and Distribution Agreement • June 26th, 1998 • Innova Pure Water Inc /Fl/ • Household appliances • Florida
SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • March 31st, 2005 • Heska Corp • Biological products, (no disgnostic substances) • Colorado
This letter confirms our agreement to interpret and supplement the Distribution Agreement as follows (capitalized terms not otherwise defined herein have the meanings ascribed to them in the Distribution Agreement):
ContractSupply and Distribution Agreement • August 14th, 2013 • Heska Corp • Biological products, (no disgnostic substances)
SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • November 14th, 2001 • Supergen Inc • Pharmaceutical preparations • California
This Supply and Development Agreement (the "Agreement") is made as of the 21st day of September, 2001 (the "Effective Date"), by and between SuperGen, Inc., ("SuperGen"), a Delaware corporation, with its principal offices at 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, and EuroGen Pharmaceuticals Ltd. ("EuroGen"), incorporated and registered in England and Wales, Companies Act 1985 registration number 4157153, with its principal offices at The Gloucestershire Innovation Centre, Southgate House, Southgate Street, Gloucester GL1 1UD, England.
AMENDMENT 20 TO THE SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • December 22nd, 2011 • Icu Medical Inc/De • Surgical & medical instruments & apparatus
This Amendment 20 (this “Amendment”), effective this 30th day of November, 2011 is made to the Supply and Distribution Agreement dated April 3, 1995, as amended, between ICU Medical Sales, Inc. (“ICU”) and Hospira, Inc. (“Hospira”) relating to the purchase and sales of certain Products (the “Agreement”).
SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • April 11th, 2013 • Kamada LTD • Pharmaceutical preparations • New York
THIS SUPPLY AND DISTRIBUTION AGREEMENT (this “Agreement”) is entered into this 18th day of July 2011, by and between Kamada Ltd., a corporation organized and existing under the laws of Israel (“Kamada”) and Kedrion S.p.A., a corporation organized and existing under the laws of the Republic of Italy (“Kedrion”), together the “Parties” and each individually a “Party.”
AMENDMENT TO SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • February 27th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations
This Amendment to Supply and Distribution Agreement (“Amendment”) dated the 13th day of March, 2012, but effective as of May 20, 2011, by and between Mylan Pharmaceuticals Inc., a West Virginia corporation located at 781 Chestnut Ridge Road, Morgantown, West Virginia 26505, USA (“Mylan”) and Insys Therapeutics, Inc., a Delaware corporation located at 10220 South 51st Street, Suite 2, Phoenix, AZ 85044 (“Insys”).
ADDENDUM NO. 1 to SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • November 28th, 2012 • Synergetics Usa Inc • Electromedical & electrotherapeutic apparatus
This Addendum No. 1 to Supply and Distribution Agreement (“Addendum No. 1”) is made as of November 15, 2006, 2006, (the “Effective Date”) by and between Synergetics USA, Inc. (f/k/a Valley Forge Scientific Corp. (referred to herein as “VFS”) and Stryker Instruments Division of Stryker Corporation, a Michigan corporation (“Distributor”). Capitalized terms used herein and not otherwise defined shall have the same meanings as given them in the Agreement (as such terms is defined below).
Amendment To License, Development, Supply and Distribution AgreementSupply and Distribution Agreement • August 3rd, 2011 • Allergan Inc • Pharmaceutical preparations
This Amendment to License, Development, Supply and Distribution Agreement (the “Amendment”), effective as of June 13, 2011 (the “Amendment Effective Date”) by and among Allergan Sales, LLC, a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan Sales”), Allergan USA, Inc., a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan USA”), Allergan, Inc., a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan, Inc.” and, collectively with Allergan Sales and Allergan USA, “Allergan”), and Spectrum Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 11500 S. Eastern Ave., Ste. 240, Henderson, Nevada 89052 (“Spectrum”).
SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • November 6th, 2014 • Biolife Solutions Inc • Electromedical & electrotherapeutic apparatus • Delaware
This Supply and Distribution Agreement (“Agreement”) is entered into as of September 29, 2014 (the “Effective Date”) by and between SAVSU Technologies, LLC, a Delaware limited liability company having its principal place of business at 1 High Country Road, Santa Fe, NM 87508 (“Seller”), and biologistex CCM, LLC, a Delaware limited liability company having its principal place of business at 3303 Monte Villa Parkway, Suite 310, Bothell WA 98021 USA (“Buyer”, and together with Seller, the “Parties”, and each, a “Party”).
FIRST AMENDMENT TO EXCLUSIVE SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • August 14th, 2006 • Cell Power Technologies Inc • Patent owners & lessors
SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • March 16th, 2007 • Orasure Technologies Inc • Surgical & medical instruments & apparatus • Delaware
THIS SUPPLY AND DISTRIBUTION AGREEMENT (this “Agreement”) is made and entered into as of this 11th day of February 2005 (“Effective Date”), by and between Abbott Laboratories, an Illinois corporation with principal offices at 100 Abbott Park Road, Abbott Park, IL, 60064-3500 (“Abbott”), and OraSure Technologies, Inc., a Delaware corporation with principal offices at 220 East First Street, Bethlehem, Pennsylvania 18015 (“OraSure”).
THIRD AMENDMENT TO THE EXCLUSIVE MANUFACTURING, SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • April 28th, 2015 • Kamada LTD • Pharmaceutical preparations
This Third Amendment to the Exclusive Manufacturing, Supply and Distribution Agreement dated August 23rd, 2010 as amended on September 6th, 2012, and May 14th, 2013, by and between Baxter Healthcare Corporation having a place of business at One Baxter Way, Westlake Village, California 91361 (hereinafter “Baxter”) and Kamada Ltd., having a place of business at Science Park, Kiryat Weizmann, 7 Sapir St., Ness-Ziona, 74036, Israel (hereinafter “Kamada”) (the "Agreement") is entered into as of this 15th day of February, 2014 (the "Effective Date"). Baxter and Kamada shall collectively be referred to as the “Parties”.
SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • March 31st, 2005 • Draxis Health Inc /Cn/ • Pharmaceutical preparations • Quebec
a company organized and existing under the laws of the Province of Ontario, having its principal place of business at 16711 Trans-Canada Highway West Kirkland, Quebec H9H 3L1
SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • August 12th, 2024 • Megola Inc • Miscellaneous chemical products • Nevada
This Supply and Distribution Agreement (“Agreement”), effective as of August 6, 2024 (the “Effective Date”), between MEGOLA, INC, a Nevada State Corporation (“Megola”), having its principal place of business at 8891 Brighton Lane Ste 108, Bonita Springs, FL 34135, and Kane & McHenry Enterprises, LLC, a Pennsylvania Corporation (“Distributor”), having its principal place of business at 4660 Elizabeth Street, Coraopolis, PA 15108, grants Distributor rights to market and sell certain Megola products in accordance with the terms of this Agreement.
Amendment to Supply and Distribution AgreementSupply and Distribution Agreement • May 12th, 2004 • Angiodynamics Inc • Surgical & medical instruments & apparatus
This Amendment to the Supply and Distribution Agreement described below is made as of April 1, 2004, by and between AngioDynamics, Inc., a Delaware corporation (“AngioDynamics”), and Biolitec, Inc., a New Jersey Corporation (“Biolitec”).
SECOND AMENDMENT TO SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • March 22nd, 2017 • Kadmon Holdings, Inc. • Pharmaceutical preparations
This Second Amendment modifies the Supply and Distribution Agreement by and between Kadmon Pharmaceuticals, LLC, a Pennsylvania Limited Liability Company (“KADMON”), with its principal place of business at 119 Commonwealth Drive, Warrendale, PA 15086 and Camber Pharmaceuticals, Inc., a Delaware company (“CAMBER”), with its principal place of business at 1031 Centennial Avenue, Piscataway, NJ 08854, effective as of February 23, 2016 and amended on May 20, 2016 (collectively, the “Agreement”). Capitalized terms not otherwise defined herein have the meanings ascribed to them in the Agreement.
SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • April 10th, 2013 • Cellular Dynamics International, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS SUPPLY AND DISTRIBUTION AGREEMENT ("Agreement"), dated June 12, 2012 (the "Effective Date"), is entered into between Life Technologies Corporation, a Delaware corporation having a place of business at 5791 Van Allen Way, Carlsbad, California 92008, U.S.A. ("LTC") and Cellular Dynamics International, Inc., a Wisconsin corporation having a place of business at University Research Park, 525 Science Drive, Suite 200, Madison, Wisconsin 53711 ("CDI"). LTC and CDI are sometimes referred to individually as a "Party" or collectively as the "Parties".
Confidential Portions of this Exhibit marked as [**] have been omitted pursuant to a request for confidentiality and filed separately with the Securities and Exchange Commission.Supply and Distribution Agreement • May 3rd, 2012 • Watson Pharmaceuticals Inc • Pharmaceutical preparations • New York
WHEREAS, PFIZER and its Affiliates own the following U.S, Patents relating to PFIZER’s drug Lipitor®: 4,681,893 (“893 Patent”), 5,273,995 (“995 Patent”), 5,686,104 (“104 Patent”), 5,969,156 (“156 Patent”) and 6,126,971 (“971 Patent”);
